Kornimate/medical-research-clean huggingface dataset:
osteoporosis awareness among nursing students

Conditions: Interventional

Summary: the aim of this clinical study is to determine the effect of scenario-based training of nursing students on awareness of osteoporosis. to this end, the most important questions to be answered in the study are * what is the level of osteoporosis awareness among nursing students at the start of the study? * does scenario-based education have an impact on osteoporosis awareness? participants: all student nurses participating in the study will first receive theoretical training on osteoporosis. at the end of the training, a scenario example prepared by the researchers on the topic of osteoporosis is worked on with the students in the experimental group. no additional intervention is carried out with the control group.

in this study, 78 nursing students randomly assigned to the experimental and control groups are first interviewed using the personal information questionnaire and the osteoporosis awareness scale. this is followed by a four-hour theoretical lesson prepared by the researchers in accordance with current literature and textbooks on osteoporosis as part of the joint and connective tissue diseases and nursing course. at the end of the theoretical lessons, a scenario example prepared by the researchers, again using current literature and case presentations, will be worked on with the students in the experimental group. no other application is made for the control group. the personal information questionnaire and the osteoporosis awareness scale will be re-administered to both groups four weeks after the end of the theoretical lesson.

Eligibility criteria:
inclusion criteria: * 18 years of age and above, * mersin university faculty of nursing 2nd year students, * have not received any other training on osteoporosis before, * willing to participate in the research, * have cognitive competence to fill out the data collection form, * those who sign the informed voluntary consent form will be included. exclusion criteria: * those under the age of 18, * not a 2nd year student at mersin university faculty of nursing, * have previously received different training on osteoporosis, * do not want to participate in the research, * do not have the cognitive ability to fill out the data collection form, * those who do not sign the informed consent form will not be included.

Keywords: scenario-supported education nursing students osteoporosis awareness
fast track therapeutic model in acute complicated appendicitis in pediatrics

Conditions: Laparoscopic Appendectomy; Complicated Appendicitis; Periappendicular Abscess

Summary: evaluate the application of the new therapeutic model post fast track surgery, in complicated acute appendicitis, in pediatric population on the rate of complications postoperative in the form of abdominal abscesses.

complicated appendicitis is defined as the finding in the intraoperative study of a perforated, gangrenous or contaminated appendix with the presence of periappendicular abscess. in november 2005, the synthesis of an "evidence-based clinical practice guide for acute appendicitis in pediatrics" at the hospital vall d'hebron, the result of a committee of experts in the field. this protocol has been the guideline for our center in recent years. currently, the therapeutic approach is based on monotherapy antibiotic management (except for drug allergies, appendicular peritonitis, immunosuppression or nosocomial acquisition) in the postoperative period, with a minimum duration of 5 days (intravenous treatment). therefore, the minimum hospital stay in these patients is expected to be equal to or more than 5 days. acute appendicitis represents the most frequent cause of acute abdomen in pediatric patients older than two years. it affects approximately 80,000 children in the european union, making appendectomy one of the most frequent non-elective pediatric interventions performed by pediatric surgeons. in recent years, several ambispective studies have been carried out at national level applying new therapeutic models that allow shortening the hospital stay by applying more lax discharge criteria and reducing the duration of intravenous antibiotic treatment, without significant alterations in the rate of postoperative complications. by reducing hospital stay, the fast-track model not only brings clinical benefits to patients, but also economic benefits to the healthcare system.

Eligibility criteria:
inclusion criteria: * ages 2 to 16 years intraoperative diagnosis of complicated appendicitis. laparoscopic appendectomy. 72 hours postoperative. leukocyte count and c-reactive protein at 72 hours post-surgery increased (minimum 20% with respect to the preoperative baseline). complete oral tolerance. pain controlled with conventional analgesia.afebrile (more than 24 hours). exclusion criteria: * history of cystic fibrosis, crohn's disease, transplant or appendicitis. chronic requiring elective technique. contraindication to the administration of amoxicillin-clavulanic acid. refusal to participate in the study by parents/legal guardians.

Keywords: complicated appendicitis
safety and exploratory efficacy study of collagen membrane with mesenchymal stem cells in the treatment of skin defects

Conditions: Wounds; Diabetic Foot Ulcers; Burns

Summary: the purpose of the present study is to evaluate the safety and exploratory efficacy of the medical collagen membrane with umbilical cord derived mesenchymal stem cells in the treatment of patients with skin defects.


Eligibility criteria:
inclusion criteria: * age between 18 and 70, borh gender. * patient able and willing to sign informed consent and comply with study procedures. * women of childbearing potential must use birth control pills, barriers or abstinence and have a negative pregnancy test. * deep partial or full thickness skin defect of at least 9 cm2 requiring surgical wound coverage due to: burn injury, diabetic foot ulcer or wounds caused by mechanical damage or iatrogenic injury. exclusion criteria: * patient refusal. * patient has a documented history of allergy or sensitivity to any of the animal products used in preparation of skin substitute. these products include bovine blood, bovine collagen, and bovine collagenase. * patient has a documented history of allergy or sensitivity to any of the antimicrobials or reagents used in preparation and application of skin substitute including the irrigation solution used before and after grafting. * patient has a current diagnosis of an invasive burn wound infection in unexcised burn wound. * patient has tunnels or sinus tracts that cannot be completely debrided. * serious primary diseases of the liver, kidney and hematopoietic system, abnormal liver function(glutamic-pyruvic transaminase(alt), glutamicoxalacetic transaminase (ast) is 2 times higher than the normal value), creatinine(cr) is higher than the upper limit of the normal value. * other clinical trial participants within 3 months. * a random blood sugar reading \>/=450 mg/dl. * investigators judge other conditions not suitable for inclusion.
the role of capsular tension ring (ctr) in anterior capsular contraction

Conditions: Retinitis Pigmentosa; Cataract

Summary: this is a randomized controlled trial to study the role of capsular tension ring in patients with retinitis pigmentosa

cataract is a common complication in retinitis pigmentosa (rp) patient especially posterior sub capsular cataract. continuous curvilinear capsulorhexis is the preferred method of capsulotomy in cataract surgery. anterior capsular contraction (aco) is a unique complication following cataract surgery. the rate of which is higher in rp patients due to the weak zonules and the increased rate of inflammation. ctr has been proven to reduce the rate of contraction. study population includes 40 eyes having rp with cataract. 20 eyes will receive ctr and the other 20 would not receive ctr. the percentage of anterior capsular contraction would be evaluated using epco software.

Eligibility criteria:
inclusion criteria: * age 35 to 65 years * typical retinitis pigmentosa * reside within a radius of 100kms from madurai * patients willing to come for follow up * patients with nuclear sclerosis grade 2 or 3 or cortical cataract or pscc exclusion criteria: * diabetic patients * traumatic cataract * uveitis * glaucoma * pseudoexfoliation * myotonic dystrophy * corneal pathology * pupil size \<6mm * intra op complications like zonular dialysis,pc rupture * rhexis not covering iol optic

Keywords: retinitis pigmentosa cataract
transfusing neonates based on platelet mass

Conditions: Thrombocytopenia

Summary: thrombocytopenia (low platelet count) is common in the neonatal intensive care unit. commonly, the decision of when to transfuse platelets is based on platelet number. recently, christensen et al (2006) proposed using transfusion guidelines based on platelet mass rather than platelet number. by using platelet size as a guide of when to give platelets, we may be able to decrease the amount platelet transfusions needed. this study is investigating using platelet size rather than platelet number as a guideline for transfusing platelets in infants who are hospitalized in a nicu (neonatal intensive care unit). after obtaining parental informed consent, thrombocytopenic infants will be randomized to one of two groups. 1: transfusion based on platelet number; 2: transfusion based on a combination of platelet number and platelet mass. in each group the decision to transfuse platelets will be made using a slightly different, yet strict set of transfusion rules. the objective is to determine the feasibility, rate of bleeding complications and compliance of transfusing neonates based on platelet mass rather than platelet number. the investigators hypothesize that transfusing platelets based on platelet mass will not increase bleeding complications and will reduce the number of transfusions in thrombocytopenic neonates.


Eligibility criteria:
inclusion criteria: * thrombocytopenic infants exclusion criteria: * major congenital anomalies

Keywords: thrombocytopenia platelet transfusion
"bilateral training in stroke patients"

Conditions: Stroke

Summary: the objective of this study was to evaluate the effects of bilateral training for upper extremity in stroke patients and to compare these effects between right and left stroke patients. a quasi experimental study conducted on community stroke survivors. a total of 24 stroke patients were included and divided into group a (right hemiplegia) (n=12) and group b (left hemiplegia) (n=12). chronic stroke patients (\>3 months), aged 30-70 years with left or right sided diagnosed stroke patients were included while patients on medication that could affect the cognitive functions or with any other cognitive impairments who are not able to follow commands were excluded. both groups received the same intervention of with bilateral arm training involving 5 functional tasks to improve the functional activities of daily living in upper extremities. fugl-meyer assessment-upper extremity tool (fma-ue) and wolf-motor function test (wmft) were used to assess as outcome measures.the measurements were obtained at baseline and after 6th week of training. data was analyzed using spss version 21.


Eligibility criteria:
inclusion criteria: * left or right-sided chronic stroke patients exclusion criteria: * patients with cognitive impairment or unable to follow commands
effectiveness of the dry needling approach in patients with tension-type headache

Conditions: Tension-Type Headache; Dry Needling

Summary: randomized single-blind clinical trial in which the treatment will be administered through 3 sessions of dry needling in the cervical, cranial, and facial musculature in patients with frequent and chronic tension-type headache.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of tension headache according to ihs exclusion criteria: * documented major trauma through medical history in the cervical area and/or recent surgery. * pregnancy. * generalized pain. * inflammatory, hormonal, or neurological disorders. * tendon disorders in the upper extremities. * severe psychiatric illnesses. * inability to complete the form in spanish. * having a pacemaker (due to the use of equipment with magnetic sensors). * specific contraindications to invasive or conservative physiotherapy (infection, fever, hypothyroidism, wounds in the puncture area, metal allergies, cancer, systemic diseases, or belonephobia). * having received physiotherapy treatment for the condition in the past month.
a study of the safety and efficacy of tobramycin for inhalation in young children with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this study's primary goals are to test the safety and effectiveness of tobramycin for inhalation (tobir) in cystic fibrosis (cf) patients who are between 6 months and 6 years of age. this drug is an antibiotic that is inhaled into the lungs by the patient. it has already been studied and approved by the fda for treatment of cf patients 6 years and older. lung fluid will be examined for bacteria before and after the 28-day treatment. the amount of bacteria before and after treatment will be compared. this will indicate whether the antibiotic was effective in killing bacteria in the lungs. once treatment begins, patients will be monitored every 2 weeks throughout the study (5 exams in 56 days). half of the patients will receive tobir, half will receive a placebo (a substance that looks like tobir but contains no medication).


Eligibility criteria:
inclusion criteria: * age at least 6 months and less than 6 years * diagnosis of cystic fibrosis with 2 clinical features consistent with cf and confirmed by either sweat chloride \>= 60 meq/l (by quantitative pilocarpine iontophoresis) or by genotype with 2 identifiable mutations consistent with cf. * one throat or sputum microbiology culture positive for pseudomonas aeruginosa (pa) within 2 weeks to 12 months prior to screening. * informed consent by parent or legal guardian. exclusion criteria: * history of adverse reaction to anesthesia or sedation. * history of aminoglycoside hypersensitivity. * history of unresolved anemia (hematocrit \< 30%) or thrombocytopenia (platelet count \< 100,000/mm3). * history of hemoptysis with 30 days prior to screening. * history of abnormal renal function (serum creatinine \> 1.5 times the upper limit of normal for age). * history of clinically documented chronic hearing loss. * administration of any investigational drug within 30 days prior to screening.

Keywords: cystic fibrosis
the effect of methylene blue infiltrating injection on anal pain after milligan-morgan surgery: a randomized controlled clinical study

Conditions: Mixed Hemorrhoids

Summary: a variety of analgesic strategies are available following mixed hemorrhoids surgery, including pharmacological interventions (7), acupuncture, moxibustion, and electroacupuncture . medications such as opioid analgesics and non-steroidal anti-inflammatory drugs (nsaids) are commonly used but can be associated with side effects including nausea, vomiting, and gastrointestinal bleeding, with long-term use potentially leading to addiction (8). complementary therapies require skilled administration and regular treatment sessions. methylene blue (mb), a cationic thiazine dye extensively utilized as a biological stain and chemical indicator, has been increasingly recognized for its potential analgesic properties (9). in the present study, methylene blue infiltrating injection (mbi) was administered to treat anal pain resulting from milligan-morgan surgery, with the aim of assessing its analgesic efficacy and safety profile.


Eligibility criteria:
inclusion criteria:①alignment with the diagnostic criteria for mixed hemorrhoids as outlined in the "american society of colon and rectal surgeons clinical practice guidelines for the management of hemorrhoids" ; ②provision of informed consent following a thorough comprehension of the study's aims; ③an age bracket of 18 to 75 years; ④satisfaction of surgical indications. - exclusion criteria:①presence of anal fistula, anal fissure, perianal abscess, enteritis, or other intestinal pathologies; ②patients with known allergies; ③impaired liver or kidney function; ④pregnancy or lactation. -

Keywords: milligan-morgan surgery
a pilot study of the utility of 3d printed masks for als subjects

Conditions: Amyotrophic Lateral Sclerosis

Summary: non-invasive ventilation (niv) is an important therapy for patients with a number of neurological diseases. specifically, niv has been shown to be an effective treatment for people with amyotrophic lateral sclerosis (als, also known as lou gehrig's disease), which is a fatal, non-curable, progressive disease of the motor neurons. however, due to changes in facial structure associated with the disease, many als patients find that traditional niv masks don't fit well. in this study, investigators will perform a feasibility study on niv mask interfaces which are custom designed for each als patient and then manufactured via 3d printing.

non-invasive ventilation (niv) is an important therapy for patients with a number of neurological diseases. specifically, for amyotrophic lateral sclerosis (als)--a fatal, non-curable, progressive disease of the motor neurons--niv represents one of the most effective treatments with a survival benefit of greater than 1 year. despite this survival advantage, and the corresponding improvement in quality of life (qol), compliance with niv can be poor. factors contributing to poor compliance to niv include bulbar onset disease and mask leaks. in addition to reduced adherence to therapy, elevated mask leaks can compromise the pressure adjustment algorithm in average volume assured pressure support (avaps) ventilation, a commonly used mode of bilevel (positive airway pressure) pap therapy in als. in an effort to increase niv compliance in subjects with neurological conditions, and specifically als, investigators hypothesize that a better fit achieved through 3d printed niv mask interfaces may improve utilization by decreasing mask leaks, decreasing the required delivery pressures and improving compliance with therapy. investigators therefore propose a feasibility study to investigate the use of 3d printing to manufacture customized niv mask interfaces for subjects with als who encounter difficulty using niv because of poorly fitting mask interfaces despite exhausting available commercial mask options.

Eligibility criteria:
inclusion criteria: 1. age greater than 18 2. ability to communicate in english 3. diagnosis of als 4. subject followed in the als clinic at university of michigan 5. current use of niv. 6. problematic mask leak defined as one of the following: a. a clinical complaint of mask leak impeding use of pap and pap use \ 10% (avaps) 7. at least 1 month of niv use exclusion criteria: 1. subjects successfully using a commercially available mask without objective or subjective leak with good compliance (average use \>6 hours per night) 2. silicone allergy

Keywords: amyotrophic lateral sclerosis, non-invasive ventilation, mask, custom, 3d-printing
modification of visual outcomes after optic neuritis in cis or ms by gilenya (moving study)

Conditions: Multiple Sclerosis

Summary: in the moving study should be examined, whether early therapeutic intervention with fingolimod (gilenya ®) after optic neuritis(on) has a favorable visual outcome as a comparative therapie with interferon beta-1b (extavia®), as measured by multifocal visual evoked potentials (mvep) after 6 month compared to baseline.


Eligibility criteria:
inclusion criteria: * diagnosis of relapsing-remitting multiple sclerosis (rrms) * ability to consent and a written approval * first acute on attack to the fit eye within 30 days before screening * age 18 - 55 years at screening * edss ≤ 6.0 * no ms attack except for on in the last 30 days before screening * no immunomodulatory therapy for at least three months (before randomization), or * strong immunomodulatory therapy with interferon beta or glatiramer acetate for at least 6 months * visus in the affected eye at least 0.1 * latency of conventional vep in the affected eye * = 115 ms or difference\> = 15 ms to the opposite side at a study at least 4 but no more than 6 weeks after onset of clinical symptoms * at least 2 t2 lesions typical of ms in a previous mri exclusion criteria: * other ms course than rrms * any condition which could interfere or prevent the mri study or other investigations * known allergy or intolerance, or other contraindication against gd-dtpa * patients with known contraindications to treatment with fingolimod (gilenya ®) or interferon beta-1b extavia ® * competing diseases which could affect visual functions such as diabetic, retinopathy, glaucoma, retinal detachment
evaluation of onset of effect in patients with severe chronic obstructive pulmonary disease (copd) treated with symbicort® compared to seretide®

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: this study is to assess the effects with two different inhaled respiratory medications with regards to improvement of lung function, symptoms and morning activities.


Eligibility criteria:
inclusion criteria: * outpatient, female or male aged ≥40 years, diagnosis of copd with symptoms for at least 2 years * fev1 ≤50% of predicted normal value, pre-bronchodilator, fev1/vc \<70% * pre-bronchodilator exclusion criteria: * current respiratory tract disorder other than copd * history of asthma or rhinitis * significant or unstable cardiovascular disorder

Keywords: copd symbicort seretide
comparative evaluation of the safety and the efficacy of 2 antimalarials depending on hiv status

Conditions: Plasmodium Falciparum Malaria

Summary: the purpose of this study is to determine the safety and efficacy of sulfadoxine-pyrimethamine (sp) versus artemether-lumefantrine (coartem) when administered to hiv+ and hiv- patients with uncomplicated p. falciparum malaria. patients will be randomised to one of the 2 treatment and followed up (until day 14 actively) for 45 days.


Eligibility criteria:
inclusion criteria: * man and non-pregnant women aged between 15 and 50. * p.falciparum mono-infection of at least 1,000 parasites/µl. * body temperature ≥ 37.5°c at the moment of enrolment or history of fever in the preceding 48 hrs. * consent from patient obtained. exclusion criteria: * pregnancy. * severe p. falciparum malaria . * documented intake of sp or coartem two weeks or less prior recruitment. * other cause(s) of fever. * evidence of underlying chronic diseases (cardiac, renal, hepatic, malnutrition). * history of allergy to study drug, or known allergy to other sulphur drugs such as co-trimoxazol.